卡波姆作为佐剂对进行性萎缩性鼻炎疫苗有效性的评价
研究将灭活支气管败血波氏杆菌与多杀性巴氏杆菌及含PMT C端和N端的重组蛋白混合,分别用ISA-15A和卡波姆971两种佐剂乳化,在小鼠模型中评价疫苗效力。Balb/C小鼠间隔14天免疫两次,二次免疫后两周采血并用产毒素多杀性巴氏杆菌攻毒,35天后安乐死采集血和组织。与ISA-15A佐剂疫苗组相比,卡波姆971P佐剂疫苗组小鼠血清中和抗体滴度更高(1:64),TNF-α、IL-6和IL-17A水平显著升高,攻毒后鼻部及器官未检测到病理变化。结果表明卡波姆佐剂疫苗提供良好保护,可诱导强体液和细胞免疫应答,作者认为其是预防进行性萎缩性鼻炎的良好候选疫苗。
要点
- 卡波姆971P佐剂疫苗组小鼠血清中和抗体滴度为1:64,高于ISA-15A佐剂疫苗组。
- 卡波姆971P佐剂疫苗组TNF-α、IL-6和IL-17A水平较ISA-15A佐剂疫苗组显著升高。
- 卡波姆971P佐剂疫苗组攻毒后鼻部及器官未检测到病理变化。
核心结论
- 卡波姆佐剂疫苗对进行性萎缩性鼻炎和多杀性巴氏杆菌感染提供良好保护,可诱导强体液和细胞免疫应答,是预防进行性萎缩性鼻炎的良好候选疫苗。
研究设计与样本
- 研究在小鼠模型中评价两种佐剂乳化的疫苗效力,Balb/C小鼠间隔14天免疫两次,二次免疫后两周采血并用产毒素多杀性巴氏杆菌攻毒,35天后安乐死采集血和组织样本。
主要发现
- 与ISA-15A佐剂疫苗组相比,卡波姆971P佐剂疫苗组小鼠血清中和抗体滴度更高(1:64),TNF-α、IL-6和IL-17A水平显著升高。
- 卡波姆971P佐剂疫苗组小鼠攻毒后鼻部及器官未检测到病理变化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Gram-negative pathogen toxigenic P. multocida causes progressive atrophic rhinitis (PAR) in swine throughout the world. Although some vaccines are being developed against PAR, their efficacy has not been evaluated using carbopol. In our study, a mixture of killed B. bronchiseptica and P. multocida bacteria, combined with recombinant proteins containing the C- and N-termini of PMT, was emulsified using two different adjuvants (ISA-15A and carbopol 971). The efficacy of these two vaccines was evaluated in a mouse model. Balb/C mice were immunized twice at a 14-day interval. Two weeks after the secondary immunization, blood samples were collected and the mice were challenged with toxigenic P. multocida. Thirty-five days later, the mice were euthanized, blood and tissue samples were collected. Compared with mice inoculated with vaccine emulsified with ISA-15A, higher titers of SN (1:64) and significantly increased levels of TNF-α, IL-6 and IL-17A were observed in mice inoculated with vaccine emulsified with the carbopol 971P. Especially, mice immunized with vaccine emulsified with the carbopol 971P had no detectable pathological changes in snouts or organs after challenge. The results demonstrated that carbopol adjuvanted vaccine provides good protection against PAR and P. multocida infection which can induce robust humoral and cell-mediated responses. We conclude that the carbopol adjuvanted vaccine is a good candidate for PAR prevention.
引用
- Zhang J, Wang M, Zhou N, et al. Evaluation of carbopol as an adjuvant on the effectiveness of progressive atrophic rhinitis vaccine. Vaccine. 2018. PMID: 29909135. doi:10.1016/j.vaccine.2018.06.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。